|
KMID : 0939920200520041112
|
|
대한암학회지
2020 Volume.52 No. 4 p.1112 ~ p.1119
|
|
|
Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
|
|
Lim Sun-Min
Kim Sang-We
Cho Byoung-Chul
Kang Jin-Hyung
Ahn Myung-Ju
Kim Dong-Wan
Kim Young-Chul
Lee Jin-Soo
Lee Jong-Seok
Lee Sung-Yong
Park Keon-Uk
An Ho-Jung
Cho Eun-Kyung
Jang Tae-Won
Kim Bong-Seog
Kim Joo-Hang
Lee Sung-Sook
Na Im-II
Yoo Seung-Soo
Lee Ki-Hyeong
|
|
|
Abstract
|
|
|
Purpose: The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti?programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program.
Materials and Methods: Previously treated patients with advanced non-squamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, survival, and safety data were collected.
Results: Two hundred ninety-nine patients were treated across 36 Korean centers. The objective response rate and disease control rate were 18% and 49%, respectively; the median progression-free survival was 2.1 months (95% confidence interval [CI], 1.87 to 3.45), and the overall survival (OS) was 13.2 months (95% CI, 10.6 to 18.9). Patients with smoking history and patients who experienced immune-related adverse events showed a prolonged OS. Cox regression analysis identified smoking history, presence of immune-related adverse events as positive factors associated with OS, while liver metastasis was a negative factor associated with OS. The safety profile was generally comparable to previously reported data.
Conclusion: This real-world analysis supports the use of nivolumab for pretreated NSCLC patients, including those with an older age.
|
|
|
KEYWORD
|
|
|
Non-small cell lung cancer, Anti?PD-1, Real-world data
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|